miR-221/222 targets cell cycle regulators, such as p27 and p57; pro-apoptotic proteins, such as BCL2 modifying factor (BMF); modulators of mammalian target of rapamycin (mTOR) pathway, such as DNA damage-inducible transcript 4 (DDIT4); and epigenetic regulators, such as HDAC6, all of which might contribute to its ability to induce NASH and HCC [89,92,93,94]. The gene discussed is MTOR; the disease is metabolic dysfunction-associated steatohepatitis.